TY - JOUR
T1 - D-PRISM
T2 - a global survey-based study to assess diagnostic and treatment approaches in pneumonia managed in intensive care
AU - for the D-PRISM Investigators
AU - National/Regional Co-ordinators
AU - Steering Committee
AU - Reyes, Luis Felipe
AU - Serrano-Mayorga, Cristian C.
AU - Zhang, Zhongheng
AU - Tsuji, Isabela
AU - De Pascale, Gennaro
AU - Prieto, Valeria Enciso
AU - Mer, Mervyn
AU - Sheehan, Elyce
AU - Nasa, Prashant
AU - Zangana, Goran
AU - Avanti, Kostoula
AU - Tabah, Alexis
AU - Shrestha, Gentle Sunder
AU - Bracht, Hendrik
AU - Fatoni, Arie Zainul
AU - Abidi, Khalid
AU - bin Sulaiman, Helmi
AU - Eshwara, Vandana Kalwaje
AU - De Bus, Liesbet
AU - Hayashi, Yoshiro
AU - Korkmaz, Pervin
AU - Ait Hssain, Ali
AU - Buetti, Niccolò
AU - Goh, Qing Yuan
AU - Kwizera, Arthur
AU - Koulenti, Despoina
AU - Nielsen, Nathan D.
AU - Povoa, Pedro
AU - Ranzani, Otavio
AU - Rello, Jordi
AU - Conway Morris, Andrew
AU - Hamed, Islam
AU - Shaban, Nesreen
AU - Yeh, Tony
AU - Buetti, Niccollò
AU - Sjovall, Fredrik
AU - Hanifa, Rashan
AU - Kuzovlev, Artem
AU - Hssain, Ali Ait
AU - Nora, David
AU - Luque, Nestor
AU - Hashmi, Madiha
AU - Buowari, Dabota
AU - Schouten, Jeroen
AU - Shrestha, Gentle
AU - Lagunes, Leonel
AU - Sulaiman, Helmi bin
AU - Viderman, Dimitry
AU - Zand, Faird
AU - Zainul, Arie
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Background: Pneumonia remains a significant global health concern, particularly among those requiring admission to the intensive care unit (ICU). Despite the availability of international guidelines, there remains heterogeneity in clinical management. The D-PRISM study aimed to develop a global overview of how pneumonias (i.e., community-acquired (CAP), hospital-acquired (HAP), and Ventilator-associated pneumonia (VAP)) are diagnosed and treated in the ICU and compare differences in clinical practice worldwide. Methods: The D-PRISM study was a multinational, survey-based investigation to assess the diagnosis and treatment of pneumonia in the ICU. A self-administered online questionnaire was distributed to intensive care clinicians from 72 countries between September to November 2022. The questionnaire included sections on professional profiles, current clinical practice in diagnosing and managing CAP, HAP, and VAP, and the availability of microbiology diagnostic tests. Multivariable analysis using multiple regression analysis was used to assess the relationship between reported antibiotic duration and organisational variables collected in the study. Results: A total of 1296 valid responses were collected from ICU clinicians, spread between low-and-middle income (LMIC) and high-income countries (HIC), with LMIC respondents comprising 51% of respondents. There is heterogeneity across the diagnostic processes, including clinical assessment, where 30% (389) did not consider radiological evidence essential to diagnose pneumonia, variable collection of microbiological samples, and use and practice in bronchoscopy. Microbiological diagnostics were least frequently available in low and lower-middle-income nation settings. Modal intended antibiotic treatment duration was 5–7 days for all types of pneumonia. Shorter durations of antibiotic treatment were associated with antimicrobial stewardship (AMS) programs, high national income status, and formal intensive care training. Conclusions: This study highlighted variations in clinical practice and diagnostic capabilities for pneumonia, particularly issues with access to diagnostic tools in LMICs were identified. There is a clear need for improved adherence to existing guidelines and standardized approaches to diagnosing and treating pneumonia in the ICU. Trial registration As a survey of current practice, this study was not registered. It was reviewed and endorsed by the European Society of Intensive Care Medicine. Graphical abstract: (Figure presented.)
AB - Background: Pneumonia remains a significant global health concern, particularly among those requiring admission to the intensive care unit (ICU). Despite the availability of international guidelines, there remains heterogeneity in clinical management. The D-PRISM study aimed to develop a global overview of how pneumonias (i.e., community-acquired (CAP), hospital-acquired (HAP), and Ventilator-associated pneumonia (VAP)) are diagnosed and treated in the ICU and compare differences in clinical practice worldwide. Methods: The D-PRISM study was a multinational, survey-based investigation to assess the diagnosis and treatment of pneumonia in the ICU. A self-administered online questionnaire was distributed to intensive care clinicians from 72 countries between September to November 2022. The questionnaire included sections on professional profiles, current clinical practice in diagnosing and managing CAP, HAP, and VAP, and the availability of microbiology diagnostic tests. Multivariable analysis using multiple regression analysis was used to assess the relationship between reported antibiotic duration and organisational variables collected in the study. Results: A total of 1296 valid responses were collected from ICU clinicians, spread between low-and-middle income (LMIC) and high-income countries (HIC), with LMIC respondents comprising 51% of respondents. There is heterogeneity across the diagnostic processes, including clinical assessment, where 30% (389) did not consider radiological evidence essential to diagnose pneumonia, variable collection of microbiological samples, and use and practice in bronchoscopy. Microbiological diagnostics were least frequently available in low and lower-middle-income nation settings. Modal intended antibiotic treatment duration was 5–7 days for all types of pneumonia. Shorter durations of antibiotic treatment were associated with antimicrobial stewardship (AMS) programs, high national income status, and formal intensive care training. Conclusions: This study highlighted variations in clinical practice and diagnostic capabilities for pneumonia, particularly issues with access to diagnostic tools in LMICs were identified. There is a clear need for improved adherence to existing guidelines and standardized approaches to diagnosing and treating pneumonia in the ICU. Trial registration As a survey of current practice, this study was not registered. It was reviewed and endorsed by the European Society of Intensive Care Medicine. Graphical abstract: (Figure presented.)
KW - Antimicrobials
KW - Bronchoscopy
KW - Community-acquired
KW - Hospital-acquired
KW - Intensive care unit (ICU)
KW - Pneumonia
KW - Surveys and questionnaires
KW - Ventilator-associated
UR - http://www.scopus.com/inward/record.url?scp=85210005694&partnerID=8YFLogxK
U2 - 10.1186/s13054-024-05180-y
DO - 10.1186/s13054-024-05180-y
M3 - Article
AN - SCOPUS:85210005694
SN - 1364-8535
VL - 28
JO - Critical Care
JF - Critical Care
IS - 1
M1 - 381
ER -